Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-55920839 · 1 trial · 2 indications
The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.
The incidence of TEAEs from treatment until the last scheduled follow-up visit will be summarized by treatment group.
| Arm | Type | Description |
|---|---|---|
| Part A: Dose 1 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo administered IV infusion Dose 1. |
| Part A: Dose 2 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo administered IV infusion Dose 2. |
| Part A: Dose 3 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo administered IV infusion Dose 3. |
| Part A: Dose 4 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo administered IV infusion Dose 4. |
| Part A: Dose 5 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo administered IV infusion Dose 5. |
| Part A: Dose 6 | EXPERIMENTAL | Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6. |
| Part B | EXPERIMENTAL | Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion. |
| Name | Type | Description |
|---|---|---|
| JNJ-55920839 | DRUG | JNJ-55920839 will be administered as either IV infusion or subcutaneous injection. |
| Placebo | DRUG | 0.9 percent (%) normal saline. |
Inclusion Criteria: Part A (Healthy Participants) * Participant must be willing/able to adhere to the study visit schedule and other requirements, prohibitions, and restrictions specified in this protocol * Participant must have a body weight in the range of 50 to 90 kilogram (kg), inclusive, and ...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
JNJ-55920839 is an investigational small molecule being developed for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development, meaning it is still being tested in clinical trials and is not yet approved for use.
JNJ-55920839 is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical development for Systemic Lupus Erythematosus.
JNJ-55920839 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with Systemic Lupus Erythematosus.
JNJ-55920839 has been studied in one clinical trial, identified as NCT02609789. This was a Phase 1 study that included a single ascending dose study in healthy participants and a multiple dose study in participants with mild to moderate Systemic Lupus Erythematosus. The trial has been completed.
JNJ-55920839 is the only name provided for this investigational drug. It is a small molecule being developed by Johnson & Johnson for Systemic Lupus Erythematosus and is currently in Phase 1 clinical trials.